Advertisement

Obesity Surgery

, Volume 19, Issue 1, pp 121–124 | Cite as

Five-Year Follow-up after Laparoscopic Roux-en-Y Gastric and Partial Ileal Bypass for Treatment of Morbid Obesity and Uncontrolled Hyperlipidemia

  • Edward D. Auyang
  • Kenric M. Murayama
  • Alexander P. NagleEmail author
Case Report

Abstract

Background

Morbid obesity is associated with significant co-morbid illnesses and mortality. Hyperlipidemia is strongly associated with atherosclerosis and cardiovascular disease. Laparoscopic Roux-en-Y gastric bypass (LRYGB) is a proven and effective procedure for the treatment of morbid obesity and its related co-morbid illnesses. In a randomized prospective clinical trial, partial ileal bypass showed sustained control of hyperlipidemia and reduced comorbidities. Given risks of surgery, pharmacologic agents are the current primary therapy for hyperlipidemia. However, a morbidly obese patient with medically refractory hyperlipidemia may benefit from a combined laparoscopic Roux-en-Y gastric bypass and partial ileal bypass. We are describing the first case of a totally laparoscopic approach.

Methods

A 56-year-old female patient with morbid obesity (BMI 45.2 kg/m2) and medically refractive hyperlipidemia underwent a combined LRYGB and partial ileal bypass in 2002. She was continuously followed for 5 years for weight profile, hyperlipidemia, post-operative complications, and morbidity.

Results

Five-year follow-up of the patient showed sustained excess body weight loss. Her lipid profile has approached normal ranges with less medication. She experienced no comorbidities related to surgery or hyperlipidemia.

Conclusions

Laparoscopic Roux-en-Y gastric bypass and partial ileal bypass may be the best option for the patient who has morbid obesity and medically refractory hyperlipidemia and should be considered for select patients.

Keywords

Roux-en-Y Laparoscopic gastric bypass Laparoscopic partial ileal bypass Hyperlipidemia POSCH Bariatrics Metabolic surgery 

References

  1. 1.
    Pender JR, Pories WJ. Epidemiology of obesity in the United States. Gastroenterol Clin N Am 2005;34:1–7.CrossRefGoogle Scholar
  2. 2.
    Linton MF, Fazio S. National Cholesterol Education Program (NCEP)—the Third Adult Treatment Panel. A practical approach to risk assessment to prevent coronary artery disease and its complications. Am J Cardiol 2003;92(1A):19i–26i.CrossRefGoogle Scholar
  3. 3.
    Schauer PR. Open and laparoscopic surgical modalities for the management of obesity. J Gastroint Surg 2003;7(4):468–75.CrossRefGoogle Scholar
  4. 4.
    Schauer PR, Ikramuddin S, Gourasch W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000;232:515–29.CrossRefGoogle Scholar
  5. 5.
    Kim TH, Daud A, Ude AO, et al. Early US outcomes of laparoscopic gastric bypass versus laparoscopic adjustable silicone gastric banding for morbid obesity. Surg Endosc 2006;20(2):202–9.CrossRefGoogle Scholar
  6. 6.
    Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. NEJM 1990;323:946–55.CrossRefGoogle Scholar
  7. 7.
    Buchwald H, Campos C, Matts JP, et al. Women in the POSCH TRIAL. Effects of aggressive cholesterol modification in women with coronary heart disease. Ann Surg 1992;216(4):389–98.CrossRefGoogle Scholar
  8. 8.
    Buchwald H, Campos C, Boen JR, et al. Disease-free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia. J Amer Coll of Cardiology 1995;25(2):351–7.CrossRefGoogle Scholar
  9. 9.
    Buchwald H, Schone J. Gastric obesity surgery combined with partial ileal bypass for hypercholesterolemia. Obesity Surgery 1997;7:313–6.CrossRefGoogle Scholar
  10. 10.
    Buchwald H, Williams SE, Matts JP, et al. Overall mortality in the program on the surgical control of the hyperlipidemias. J Am Coll Surg 2002;195(3):327–31.CrossRefGoogle Scholar
  11. 11.
    Moghadasian MH, Frohlich JJ, Saleem M, et al. Surgical management of dyslipidemia: clinical and experimental evidence. J Investigative Surgery 2001;14:71–8.CrossRefGoogle Scholar
  12. 12.
    Austin MA, Hutter CM, Zimmern RL, et al. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidem 2004;160:407–20.CrossRefGoogle Scholar
  13. 13.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 1994;344(8934):1383–9.Google Scholar
  14. 14.
    Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301–7.CrossRefGoogle Scholar
  15. 15.
    Sweeney ME, Johnson RR. Ezetemibe: an update on the mechanism of action, pharmacokinetics, and recent clinical trials. Expert Opin Durg Metab Toxicol 2007;3(3):441–50.CrossRefGoogle Scholar
  16. 16.
    Dachtler J, Johnston D, Halstead JC, et al. Partial ileal resection for hypercholesterolaemia in patients undergoing surgery obesity. Brit J Surg 1999;86:1256–8.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Edward D. Auyang
    • 1
  • Kenric M. Murayama
    • 2
  • Alexander P. Nagle
    • 1
    Email author
  1. 1.Department of SurgeryNorthwestern University Feinberg School of MedicineChicagoUSA
  2. 2.Department of SurgeryUniversity of HawaiiHonoluluUSA

Personalised recommendations